Evidence map›Paper›PMID 31694894›Full record

ReviewThe oncologist2020

Brain Metastases from Biliary Tract Cancers: A Case Series and Review of the Literature in the Genomic Era.

Megan R D'Andrea, Corey M Gill, Melissa Umphlett, Nadejda M Tsankova, Mary Fowkes, Joshua B Bederson, Priscilla K Brastianos, Raj K Shrivastava

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Megan R D'AndreaDepartment of Neurosurgery, Mount Sinai Medical Center, New York, New York, USA.ORCID 0000-0002-7371-4739
Corey M GillDepartment of Neurosurgery, Mount Sinai Medical Center, New York, New York, USA.
Melissa UmphlettDepartment of Pathology, Mount Sinai Medical Center, New York, New York, USA.
Nadejda M TsankovaDepartment of Pathology, Mount Sinai Medical Center, New York, New York, USA.
Mary FowkesDepartment of Pathology, Mount Sinai Medical Center, New York, New York, USA.
Joshua B BedersonDepartment of Neurosurgery, Mount Sinai Medical Center, New York, New York, USA.
Priscilla K BrastianosDepartment of Neurology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Raj K ShrivastavaDepartment of Neurosurgery, Mount Sinai Medical Center, New York, New York, USA.
Mount Sinai Medical Center · USMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBiliary tract cancers (BTCs) are highly fatal malignancies that make up less than 1% of all cancers. BTC is often diagnosed at an unresectable stage; surgical resection remains the only definitive treatment. Brain metastases (BMs) from BTC are extremely rare, and few studies on patients with BMs from BTC exist. The aim of this study was to identify clinical characteristics associated with poor prognosis for patients with BMs from BTC. MATERIALS AND

methodsWe performed a retrospective review of electronic medical records for patients with BMs from BTC managed at Mount Sinai Hospital from 2000 to 2017. Data on patient characteristics, magnetic resonance imaging findings, treatment regimens, and clinical outcomes were analyzed.

resultsWe identified 1,910 patients with BTC. Nine patients developed BMs, with an incidence of 0.47%. Of these nine patients, six had intrahepatic cholangiocarcinoma, two had extrahepatic cholangiocarcinoma, and one had gallbladder cancer. Six (66.7%) patients had one BM, one (11.1%) patient had two BMs, and two (22.2%) patients had three or more BMs. Four (44.4%) patients underwent BM resection, and seven (77.8%) received BM radiation. Median overall survival from time of BM diagnosis was 3.8 months (95% confidence interval 0.1-16.9).

conclusionDevelopment of BMs from BTC is rare; however, prognosis is less than 4 months. BM diagnosis can occur within 2 years of primary diagnosis. As targeted therapeutics emerge, future studies ought to focus on identifying genomic BM markers associated with BTC subtypes. IMPLICATIONS FOR PRACTICE: In the largest retrospective study of biliary tract cancer brain metastases, the clinical presentation and outcomes are reported of nine patients with an extremely rare clinical entity. The genomic literature and potential therapeutic targets for these patients with limited treatment options is comprehensively and exhaustively discussed.

Indexed as

Bile Duct NeoplasmsBiliary Tract NeoplasmsBrain NeoplasmsGenomicsHumansRetrospective StudiesBiliary tract cancerBrain metastasesCholangiocarcinomaGallbladder cancerGenomics

Identifiers

PMID31694894
PMCPMC7216433
OpenAlexW2984100338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.